Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia

Jennifer L. Whitwell, Joseph R. Duffy, Edythe A. Strand, Mary M. Machulda, Matthew L. Senjem, Christopher G. Schwarz, Robert Reid, Matthew C. Baker, Ralph B. Perkerson, Val J. Lowe, Rosa Rademakers, Clifford R. Jack, Keith A. Josephs

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

Logopenic primary progressive aphasia (lvPPA) is a progressive language disorder characterized by anomia, difficulty repeating complex sentences, and phonological errors. The majority, although not all, lvPPA patients have underlying Alzheimer's disease. We aimed to determine whether clinical or neuroimaging features differ according to the deposition of Aβ on Pittsburgh-compound B PET in lvPPA. Clinical features, patterns of atrophy on MRI, hypometabolism on FDG-PET, and white matter tract degeneration were compared between six PiB-negative and 20 PiB-positive lvPPA patients. PiB-negative patients showed more asymmetric left-sided patterns of atrophy, hypometabolism and white matter tract degeneration, with greater left anteromedial temporal and medial prefrontal involvement, than PiB-positive patients. PiB-positive patients showed greater involvement of right temporoparietal and frontal lobes. There was very little evidence for clinical differences between the groups. Strikingly asymmetric neuroimaging findings with relatively preserved right hemisphere may provide clues that AD pathology is absent in lvPPA.

Original languageEnglish (US)
Pages (from-to)45-53
Number of pages9
JournalBrain and Language
Volume142
DOIs
StatePublished - Mar 1 2015

Keywords

  • Beta-amyloid
  • FDG-PET
  • Logopenic
  • Magnetic resonance imaging
  • Pittsburgh compound B
  • Primary progressive aphasia
  • Progranulin

ASJC Scopus subject areas

  • Experimental and Cognitive Psychology
  • Language and Linguistics
  • Linguistics and Language
  • Cognitive Neuroscience
  • Speech and Hearing

Fingerprint

Dive into the research topics of 'Clinical and neuroimaging biomarkers of amyloid-negative logopenic primary progressive aphasia'. Together they form a unique fingerprint.

Cite this